EUVIMEDEUVIMED entdecken
Open Access

EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT

Lei Xin, Yanli Tan, Yuanxue Zhu, Xiaoteng Cui, Qixue Wang, Jixing Zhao, Shaohui Tian, Can Xu, Menglin Xiao, Biao Hong, Jianglong Xu, Xiaoye Yuan und 3 weitere

Neuro-Oncology · 02.11.2023 · 25 (11) · 1976-1988

DOI: 10.1093/neuonc/noad102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 05.06.2023. Verfasst von Lei Xin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, China. Hauptthemen laut MEDLINE: Glioblastoma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Tianjin Key R&D Plan of Science and Technology, Science and Technology Program of Hebei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Temozolomide (TMZ) treatment efficacy in glioblastoma (GBM) has been limited by resistance. The level of O-6-methylguanine-DNA methyltransferase (MGMT) and intrinsic DNA damage repair factors are important for the TMZ response in patients. Here, we reported a novel compound, called EPIC-0307, that increased TMZ sensitivity by inhibiting specific DNA damage repair proteins and MGMT expression.

Methods

EPIC-0307 was derived by molecular docking screening. RNA immunoprecipitation (RIP), and chromatin immunoprecipitation by RNA (ChIRP) assays were used to verify the blocking effect. Chromatin immunoprecipitation (ChIP) and co-immunoprecipitation (Co-IP) assays were performed to explore the mechanism of EPIC-0307. A series of in vivo and in vitro experiments were designed to evaluate the efficacy of EPIC-0307 in sensitizing GBM cells to TMZ.

Results

EPIC-0307 selectively disrupted the binding of PRADX to EZH2 and upregulated the expression of P21 and PUMA, leading to cell cycle arrest and apoptosis in GBM cells. EPIC-0307 exhibited a synergistic inhibitory effect on GBM when combined with TMZ by downregulating TMZ-induced DNA damage repair responses and epigenetically silencing MGMT expression through modulating the recruitment of ATF3-pSTAT3-HDAC1 regulatory complex to the MGMT promoter. EPIC-0307 demonstrated significant efficacy in suppressing the tumorigenesis of GBM cells, restoring TMZ sensitivity.

Conclusion

This study identified a potential small-molecule inhibitor (SMI) EPIC-0307 that selectively disrupted the PRADX–EZH2 interaction to upregulate expressions of tumor suppressor genes, thereby exerting its antitumor effects on GBM cells. EPIC-0307 treatment also increased the chemotherapeutic efficacy of TMZ by epigenetically downregulating DNA repair-associate genes and MGMT expression in GBM cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHumansTemozolomideAntineoplastic Agents, AlkylatingMolecular Docking SimulationDNA RepairDNA Repair EnzymesO(6)-Methylguanine-DNA MethyltransferaseDNA Modification MethylasesRNACell Line, TumorDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinTumor Suppressor Proteins

Stichwörter der Autor:innen

DNA repairMGMTglioblastomasmall-molecule inhibitortemozolomide

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDNA Repair EnzymesO(6)-Methylguanine-DNA MethyltransferaseDNA Modification MethylasesRNAEZH2 protein, humanEnhancer of Zeste Homolog 2 ProteinMGMT protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • Department of Neurosurgery, Affiliated Hospital of Hebei University, Baoding 071000, China.
  • Clinical Medical College, Hebei University, Baoding 071000, China.
  • Hebei Key Laboratory of Precise Diagnosis and Treatment of Glioma, Baoding 071000, China.
  • Department of Pathology, Hebei University School of Basic Medical Sciences, Baoding 071000, China.
  • Department of Pathology, Affiliated Hospital of Hebei University, Baoding 071000, China.
  • Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.

ORCID-Profile: Chunsheng Kang

Förderung

  • National Natural Science Foundation of China
  • Tianjin Key R&D Plan of Science and Technology
  • Science and Technology Program of Hebei
  • Science and Technology Development Fund
  • Hebei Province Graduate Innovation

Zitieren

APA

Xin, L., Tan, Y., Zhu, Y., Cui, X., Wang, Q., Zhao, J., Tian, S., Xu, C., Xiao, M., Hong, B., Xu, J., Yuan, X., Wang, C., Kang, C., & Fang, C. (2023). EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology, 25(11), 1976-1988. https://doi.org/10.1093/neuonc/noad102

Vancouver

Xin L, Tan Y, Zhu Y, Cui X, Wang Q, Zhao J, et al. EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT. Neuro-Oncology. 2023;25(11):1976-1988. doi:10.1093/neuonc/noad102

BibTeX
@article{Xin2023,
  author = {Xin, Lei and Tan, Yanli and Zhu, Yuanxue and Cui, Xiaoteng and Wang, Qixue and Zhao, Jixing and Tian, Shaohui and Xu, Can and Xiao, Menglin and Hong, Biao and Xu, Jianglong and Yuan, Xiaoye and Wang, Changsheng and Kang, Chunsheng and Fang, Chuan},
  title = {EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {11},
  pages = {1976--1988},
  doi = {10.1093/neuonc/noad102}
}
Kostenlos starten →